AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KAUG 192 min read$SRXH

SRX GLOBAL INC. ANNOUNCES FISCAL THIRD QUARTER 2026 FINANCIAL RESULTS

SRX Global Inc. (SRXH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SRX GLOBAL INC. ANNOUNCES FISCAL THIRD QUARTER 2026 FINANCIAL RESULTS Net Asset Value (“NAV”) of $62.9 million, or $3.22 per Common Share, Exceeding Preliminary Estimate of $3.07 per Share 1 Ended the Quarter with $36.7 million of Cash, Cash Equivalents and Restricte

Original reporting
SEC EDGAR 8-K
Published Aug 19, 2026, 3:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 3:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$SRXH
Neutral
medium confidence
Mentioned
$SRXH
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SRXHNeutralMed
01

Why it matters

The filing provides the first public disclosure of Q3 results, cash position, NAV, and a new dividend, offering fresh data for valuation.

02

Market read

Provides primary financial data for a micro‑cap, potentially influencing short‑term trading decisions.

03

What to watch

Integration risk of the EMJX acquisition and performance of the Halo business could affect future NAV.

Relevance 7/10Novelty 8/10Timing: filed Aug 19, 2026 (post‑quarter release)

Background

SRX Global is an AI‑driven investment platform that recently acquired EMJX and operates the Halo digital‑asset business.

Company-level read

Ticker impact

$SRXHNeutralMedium confidence
Context

SRX Global reported its Q3 2026 financial results, including NAV $62.9M, cash $36.7M, a 10M share repurchase program and a $0.05 dividend.

Expected impact

Potential modest upside if investors value the dividend and liquidity; downside risk if earnings miss expectations.

Evidence & confidence

The filing provides fresh balance sheet data and a dividend, but earnings remain loss-making, suggesting limited immediate price move.

Market effects

Sector

Highlights growing interest in AI‑enabled asset platforms within the alternative investment sector.

Regional

Limited to U.S. micro‑cap investors; no broader regional effect.

Global

Minimal, as the company is small and primarily U.S. listed.

Counterpoint

What could challenge this read

The dividend and cash cushion may be a distraction; continued losses could pressure the stock.

Key entities

  • company
    SRX Global Inc.

    Issuer of the 8‑K filing and subject of the article.

  • acquired company
    EMJX

    AI‑enabled digital‑asset treasury platform acquired by SRX.

Read at source← All news

Related articles

OCT 26
$SRXHHighAI 8/10

UC Davis makes an experimental cancer treatment. Its new role is expected to expand trial recruitment.

UC Davis has been activated as a clinical trial site for CER-1236, an experimental cancer treatment, and will also serve as its primary manufacturing site. This is expected to expand patient recruitment and streamline logistics. SRX Global (SRXH) announced this milestone, which follows its agreement to acquire CERo Therapeutics (CERO). Preliminary trial results show no severe adverse events, but are not yet sufficient to establish safety or efficacy.

stocktitan.net2 min
OCT 7
$SRXHHigh

SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies

SRX Global (SRXH) will acquire CERo Therapeutics, a cellular immunotherapy company, to accelerate development of CER-1236 for blood cancers. The deal combines SRX's public infrastructure with CERo's oncology platform, aiming to enhance capital access and operational resources. CER-1236 is in Phase 1 trials, with preliminary data showing no dose-limiting toxicities in recent cohorts. The transaction is subject to closing conditions and regulatory approvals.

globenewswire.com2 min
AUG 7
$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

rttnews.com7 min
JUN 23
$SRXHMed

SRx Health Solutions, Inc.: SRX Global Makes Strategic Investment in Clinical-Stage Biodefense Company, ARMR Sciences

SRX Global (NYSE American: SRXH) said it made a strategic investment in clinical-stage biodefense company ARMR Sciences. ARMR’s lead candidate ARMR-100, in a Phase 1/2 trial, recently reported generating an anti-fentanyl immune response in humans with favorable safety data. The company plans to start evaluating protection against fentanyl later in 2026.

finanznachrichten.de3 min
JUN 8
$SRXHMedAI 8/10

SRx Health Solutions Acquires 4.99% of Smartkem, Inc. (NASDAQ: SMTK)

SRx Health Solutions (NYSE American: SRXH) said it acquired 4.99% of Smartkem (NASDAQ: SMTK) via a shelf take down, and also bought convertible preferred securities in a non-brokered private placement, according to the company. SRx noted it filed an SEC Form S-4 to register shares for the proposed transaction involving EMJ Crypto Technologies (EMJX).

manilatimes.net4 min